DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company operating in the healthcare diagnostics sector, focused on non-invasive genomic testing for skin cancer detection, including its Pigmented Lesion Assay designed for early melanoma identification. The company filed an annual report on Form 10-K with the SEC on June 29, 2018, under accession number 0001144204-18-036605, covering its operations through that fiscal year. DermTech completed a SPAC business combination that brought it to public markets, with DMTK subsequently trading on Nasdaq as a commercial-stage molecular diagnostics platform targeting dermatologists and pathology labs. The company is classified within the healthcare and life sciences sector. For complete SPAC deal history, sponsor details, filing timelines, and ongoing data on DMTK, create a free account at SpacDesk.